Zacks Investment Research upgraded shares of Myomo (NYSEAMERICAN:MYO) from a hold rating to a buy rating in a report released on Thursday. The firm currently has $4.25 price objective on the stock.
According to Zacks, “Myomo, Inc. is a commercial stage medical robotics company. It offers expanded mobility which suffering from neurological disorders and upper limb paralysis. The company develops and markets the MyoPro(R) product line of lightweight, non-invasive, powered arm braces to restore function in the paralyzed or weakened arms and hands of individuals. Myomo, Inc. is headquartered in Cambridge,Massachusetts. “
A number of other equities analysts have also recently issued reports on MYO. HC Wainwright set a $12.00 target price on Myomo and gave the stock a buy rating in a report on Thursday, March 8th. Roth Capital initiated coverage on Myomo in a report on Friday, March 9th. They set a buy rating and a $9.00 target price for the company.
Hedge funds have recently added to or reduced their stakes in the business. Virtu Financial LLC acquired a new position in shares of Myomo during the 4th quarter worth about $124,000. Sequoia Financial Advisors LLC acquired a new position in shares of Myomo during the 4th quarter worth about $257,000. Finally, Hudson Bay Capital Management LP acquired a new position in shares of Myomo during the 4th quarter worth about $294,000.
COPYRIGHT VIOLATION NOTICE: This news story was originally reported by Ticker Report and is the sole property of of Ticker Report. If you are accessing this news story on another domain, it was stolen and republished in violation of US and international trademark & copyright law. The original version of this news story can be accessed at https://www.tickerreport.com/banking-finance/3298163/myomo-myo-upgraded-at-zacks-investment-research.html.
Myomo Company Profile
Myomo, Inc is a United States-based medical device company specializing in myoelectric orthotics for people with neurological disorders. The Company’s products help to restore function in individuals with neuromuscular conditions, such as brachial plexus injury, spinal cord injury, multiple sclerosis and stroke.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Myomo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myomo and related companies with MarketBeat.com's FREE daily email newsletter.